Key clinical point: Natural killer (NK) cell subsets, particularly CD56bright NK cells, were associated with relapse outcomes after tyrosine kinase inhibitor (TKI) discontinuation in patients with chronic-phase chronic myeloid leukemia (CML-CP). Moreover, interferon-a therapy gradually increased levels of CD56bright NK cells.

Major finding: Among patients who did not receive interferon-a therapy, the nonrelapsed vs relapsed patients had a significantly higher proportion of CD3-CD56+ NK cells (P = .016), particularly CD3-CD56dimCD16+ NK cells (P = .017), at 1 month after TKI discontinuation. Patients who received interferon-a therapy showed an increase in CD56bright NK cells at 3- and 6- months post-therapy vs pre-therapy (P < .05).

Study details: Findings are from a retrospective analysis of 34 patients with CML-CP who discontinued TKI therapy after 3 or more years and at least 2 years of MR4.5. Twelve patients received interferon-a therapy post-TKI discontinuation.

Disclosures: This study was supported by the Capital Characteristic Clinic Project Foundation. The authors declared no conflict of interests.

Source: Kong J et al. Ann Hematol. 2021 Jul 19. doi: 10.1007/s00277-021-04606-9.

Key clinical point: Natural killer (NK) cell subsets, particularly CD56bright NK cells, were associated with relapse outcomes after tyrosine kinase inhibitor (TKI) discontinuation in patients with chronic-phase chronic myeloid leukemia (CML-CP). Moreover, interferon-a therapy gradually increased levels of CD56bright NK cells.

Major finding: Among patients who did not receive interferon-a therapy, the nonrelapsed vs relapsed patients had a significantly higher proportion of CD3-CD56+ NK cells (P = .016), particularly CD3-CD56dimCD16+ NK cells (P = .017), at 1 month after TKI discontinuation. Patients who received interferon-a therapy showed an increase in CD56bright NK cells at 3- and 6- months post-therapy vs pre-therapy (P < .05).

Study details: Findings are from a retrospective analysis of 34 patients with CML-CP who discontinued TKI therapy after 3 or more years and at least 2 years of MR4.5. Twelve patients received interferon-a therapy post-TKI discontinuation.

Disclosures: This study was supported by the Capital Characteristic Clinic Project Foundation. The authors declared no conflict of interests.

Source: Kong J et al. Ann Hematol. 2021 Jul 19. doi: 10.1007/s00277-021-04606-9.

Key clinical point: Natural killer (NK) cell subsets, particularly CD56bright NK cells, were associated with relapse outcomes after tyrosine kinase inhibitor (TKI) discontinuation in patients with chronic-phase chronic myeloid leukemia (CML-CP). Moreover, interferon-a therapy gradually increased levels of CD56bright NK cells.

Major finding: Among patients who did not receive interferon-a therapy, the nonrelapsed vs relapsed patients had a significantly higher proportion of CD3-CD56+ NK cells (P = .016), particularly CD3-CD56dimCD16+ NK cells (P = .017), at 1 month after TKI discontinuation. Patients who received interferon-a therapy showed an increase in CD56bright NK cells at 3- and 6- months post-therapy vs pre-therapy (P < .05).

Study details: Findings are from a retrospective analysis of 34 patients with CML-CP who discontinued TKI therapy after 3 or more years and at least 2 years of MR4.5. Twelve patients received interferon-a therapy post-TKI discontinuation.

Disclosures: This study was supported by the Capital Characteristic Clinic Project Foundation. The authors declared no conflict of interests.

Source: Kong J et al. Ann Hematol. 2021 Jul 19. doi: 10.1007/s00277-021-04606-9.

Key clinical point: Among patients with advanced phase chronic myeloid leukemia (CML), long-term survival after hematopoietic stem cell transplantation (HSCT) was influenced by donor age, CD34⁺ cell dose in the graft, and blast crisis (BC) at HSCT.

Major finding: At 15 years, overall survival (OS) and progression-free survival were 34% (95% confidence interval [CI], 22%-46%) and 26% (95% CI, 16%-36%), respectively. Donor age above 36 years (hazard ratio [HR], 1.74; P = .02), BC at HSCT (HR, 1.85; P = .01), and lower CD34⁺ cell dose in the graft (HR using continuous variables, 1.12; HR using categorical variables, 2.14; both P < .01) were associated with inferior OS.

Study details: Findings are from a retrospective analysis of 147 patients with advanced CML (BC, n=37; accelerated phase, n=40; second or higher chronic phase, n=70) who underwent HSCT between 1990 and 2018.

Disclosures: Open Access funding was enabled and organized by Projekt DEAL. The authors declared no conflict of interests.

Source: Niederwieser C et al. Bone Marrow Transplant. 2021 Jul 30. doi: 10.1038/s41409-021-01410-x.

Key clinical point: Among patients with advanced phase chronic myeloid leukemia (CML), long-term survival after hematopoietic stem cell transplantation (HSCT) was influenced by donor age, CD34⁺ cell dose in the graft, and blast crisis (BC) at HSCT.

Major finding: At 15 years, overall survival (OS) and progression-free survival were 34% (95% confidence interval [CI], 22%-46%) and 26% (95% CI, 16%-36%), respectively. Donor age above 36 years (hazard ratio [HR], 1.74; P = .02), BC at HSCT (HR, 1.85; P = .01), and lower CD34⁺ cell dose in the graft (HR using continuous variables, 1.12; HR using categorical variables, 2.14; both P < .01) were associated with inferior OS.

Study details: Findings are from a retrospective analysis of 147 patients with advanced CML (BC, n=37; accelerated phase, n=40; second or higher chronic phase, n=70) who underwent HSCT between 1990 and 2018.

Disclosures: Open Access funding was enabled and organized by Projekt DEAL. The authors declared no conflict of interests.

Source: Niederwieser C et al. Bone Marrow Transplant. 2021 Jul 30. doi: 10.1038/s41409-021-01410-x.

Key clinical point: Among patients with advanced phase chronic myeloid leukemia (CML), long-term survival after hematopoietic stem cell transplantation (HSCT) was influenced by donor age, CD34⁺ cell dose in the graft, and blast crisis (BC) at HSCT.

Major finding: At 15 years, overall survival (OS) and progression-free survival were 34% (95% confidence interval [CI], 22%-46%) and 26% (95% CI, 16%-36%), respectively. Donor age above 36 years (hazard ratio [HR], 1.74; P = .02), BC at HSCT (HR, 1.85; P = .01), and lower CD34⁺ cell dose in the graft (HR using continuous variables, 1.12; HR using categorical variables, 2.14; both P < .01) were associated with inferior OS.

Study details: Findings are from a retrospective analysis of 147 patients with advanced CML (BC, n=37; accelerated phase, n=40; second or higher chronic phase, n=70) who underwent HSCT between 1990 and 2018.

Disclosures: Open Access funding was enabled and organized by Projekt DEAL. The authors declared no conflict of interests.

Source: Niederwieser C et al. Bone Marrow Transplant. 2021 Jul 30. doi: 10.1038/s41409-021-01410-x.

Key clinical point: Thyroid abnormalities were more frequently observed in patients with chronic-phase chronic myeloid leukemia (CML-CP) on second-generation tyrosine kinase inhibitor (TKI) therapy vs imatinib and were associated with better treatment response.

Major finding: Hashimoto’s thyroiditis (HT; 30.4%) was more prevalent with nilotinib or dasatinib vs imatinib treatment (43.75% vs 18.9%; P = .03). The incidence of deep molecular response (DMR) was higher (73.1% vs 26.9%) and that of major molecular response (MMR) was lower (11.6% vs 88.4%) in patients with vs without thyroid alterations (P = .0001). HT was more prevalent in patients with DMR vs MMR (69.2% vs 7%; P = .0001).

Study details: Findings are from an analysis of 69 adult patients with Philadelphia chromosome-positive CML-CP treated with imatinib (n=37), nilotinib (n=21), or dasatinib (n=11) as first- or second-line therapy.

Disclosures: No funding was received for this study. Open access funding was provided by Universita degli Studi di Cagliari. The authors declared no conflict of interests.

Source: Rodia R et al. J Endocrinol Invest. 2021 Jul 20. doi: 10.1007/s40618-021-01613-5.

Key clinical point: Thyroid abnormalities were more frequently observed in patients with chronic-phase chronic myeloid leukemia (CML-CP) on second-generation tyrosine kinase inhibitor (TKI) therapy vs imatinib and were associated with better treatment response.

Major finding: Hashimoto’s thyroiditis (HT; 30.4%) was more prevalent with nilotinib or dasatinib vs imatinib treatment (43.75% vs 18.9%; P = .03). The incidence of deep molecular response (DMR) was higher (73.1% vs 26.9%) and that of major molecular response (MMR) was lower (11.6% vs 88.4%) in patients with vs without thyroid alterations (P = .0001). HT was more prevalent in patients with DMR vs MMR (69.2% vs 7%; P = .0001).

Study details: Findings are from an analysis of 69 adult patients with Philadelphia chromosome-positive CML-CP treated with imatinib (n=37), nilotinib (n=21), or dasatinib (n=11) as first- or second-line therapy.

Disclosures: No funding was received for this study. Open access funding was provided by Universita degli Studi di Cagliari. The authors declared no conflict of interests.

Source: Rodia R et al. J Endocrinol Invest. 2021 Jul 20. doi: 10.1007/s40618-021-01613-5.

Key clinical point: Thyroid abnormalities were more frequently observed in patients with chronic-phase chronic myeloid leukemia (CML-CP) on second-generation tyrosine kinase inhibitor (TKI) therapy vs imatinib and were associated with better treatment response.

Major finding: Hashimoto’s thyroiditis (HT; 30.4%) was more prevalent with nilotinib or dasatinib vs imatinib treatment (43.75% vs 18.9%; P = .03). The incidence of deep molecular response (DMR) was higher (73.1% vs 26.9%) and that of major molecular response (MMR) was lower (11.6% vs 88.4%) in patients with vs without thyroid alterations (P = .0001). HT was more prevalent in patients with DMR vs MMR (69.2% vs 7%; P = .0001).

Study details: Findings are from an analysis of 69 adult patients with Philadelphia chromosome-positive CML-CP treated with imatinib (n=37), nilotinib (n=21), or dasatinib (n=11) as first- or second-line therapy.

Disclosures: No funding was received for this study. Open access funding was provided by Universita degli Studi di Cagliari. The authors declared no conflict of interests.

Source: Rodia R et al. J Endocrinol Invest. 2021 Jul 20. doi: 10.1007/s40618-021-01613-5.

Key clinical point: Achievement of BCR-ABL1 less than or equal to 0.16%^IS at 6 months was predictive of future stable molecular response 4.5 (MR4.5) among patients with chronic myeloid leukemia (CML) receiving first-line imatinib therapy.

Major finding: Achievement of a molecular response of BCR-ABL1 less than or equal to 0.16%^IS predicted future stable MR4.5 (odds ratio, 3.1; P less than .001). At 8 years, patients with BCR-ABL1 less than or equal to 0.16%^IS vs more than 0.16%^IS at 6 months of imatinib treatment were more likely to achieve stable MR4.5 (65.8% vs 17.2%; P < .0001).

Study details: Findings are from a retrospective analysis of 593 patients with CML treated with frontline imatinib between 2000 and 2016.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Nee A et al. Leuk Lymphoma. 2021 Aug 11. doi: 10.1080/10428194.2021.1961234.

Key clinical point: Achievement of BCR-ABL1 less than or equal to 0.16%^IS at 6 months was predictive of future stable molecular response 4.5 (MR4.5) among patients with chronic myeloid leukemia (CML) receiving first-line imatinib therapy.

Major finding: Achievement of a molecular response of BCR-ABL1 less than or equal to 0.16%^IS predicted future stable MR4.5 (odds ratio, 3.1; P less than .001). At 8 years, patients with BCR-ABL1 less than or equal to 0.16%^IS vs more than 0.16%^IS at 6 months of imatinib treatment were more likely to achieve stable MR4.5 (65.8% vs 17.2%; P < .0001).

Study details: Findings are from a retrospective analysis of 593 patients with CML treated with frontline imatinib between 2000 and 2016.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Nee A et al. Leuk Lymphoma. 2021 Aug 11. doi: 10.1080/10428194.2021.1961234.

Key clinical point: Achievement of BCR-ABL1 less than or equal to 0.16%^IS at 6 months was predictive of future stable molecular response 4.5 (MR4.5) among patients with chronic myeloid leukemia (CML) receiving first-line imatinib therapy.

Major finding: Achievement of a molecular response of BCR-ABL1 less than or equal to 0.16%^IS predicted future stable MR4.5 (odds ratio, 3.1; P less than .001). At 8 years, patients with BCR-ABL1 less than or equal to 0.16%^IS vs more than 0.16%^IS at 6 months of imatinib treatment were more likely to achieve stable MR4.5 (65.8% vs 17.2%; P < .0001).

Study details: Findings are from a retrospective analysis of 593 patients with CML treated with frontline imatinib between 2000 and 2016.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Nee A et al. Leuk Lymphoma. 2021 Aug 11. doi: 10.1080/10428194.2021.1961234.

Key clinical point: Majority of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) who switched from frontline second-generation (2G) tyrosine kinase inhibitor (TKI) to alternative TKIs because of intolerance or resistance were able to achieve or maintain favorable clinical outcomes.

Major finding: Among patients who switched because of intolerance, 88% achieved or maintained a major molecular response (MMR) with 5-year progression-free survival (PFS) and overall survival (OS) of 90.5% (95% confidence interval [CI], 90.4%-90.6%) and 95.2% (95% CI, 95.1%-95.3%), respectively. Among patients who switched because of resistance, 50% achieved or maintained an MMR with 5-year PFS and OS of 80.4% (95% CI, 80.2%-80.6%) and 80.0% (95% CI, 79.8%-80.2%).

Study details: Findings are from a retrospective analysis of 232 patients with newly diagnosed CML-CP treated with frontline 2G-TKI (dasatinib, n=187; nilotinib, n=45) who subsequently switched to alternative TKI.

Disclosures: This study was supported by Pharmacy Services, Alberta Health Services. K Jamani and L Savoie received honoraria from Novartis, Pfizer, Bristol Myers Squibb, and Paladin.

Source: Ma CE et al. Leuk Res. 2021 Jul 24. doi: 10.1016/j.leukres.2021.106674.

Key clinical point: Majority of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) who switched from frontline second-generation (2G) tyrosine kinase inhibitor (TKI) to alternative TKIs because of intolerance or resistance were able to achieve or maintain favorable clinical outcomes.

Major finding: Among patients who switched because of intolerance, 88% achieved or maintained a major molecular response (MMR) with 5-year progression-free survival (PFS) and overall survival (OS) of 90.5% (95% confidence interval [CI], 90.4%-90.6%) and 95.2% (95% CI, 95.1%-95.3%), respectively. Among patients who switched because of resistance, 50% achieved or maintained an MMR with 5-year PFS and OS of 80.4% (95% CI, 80.2%-80.6%) and 80.0% (95% CI, 79.8%-80.2%).

Study details: Findings are from a retrospective analysis of 232 patients with newly diagnosed CML-CP treated with frontline 2G-TKI (dasatinib, n=187; nilotinib, n=45) who subsequently switched to alternative TKI.

Disclosures: This study was supported by Pharmacy Services, Alberta Health Services. K Jamani and L Savoie received honoraria from Novartis, Pfizer, Bristol Myers Squibb, and Paladin.

Source: Ma CE et al. Leuk Res. 2021 Jul 24. doi: 10.1016/j.leukres.2021.106674.

Key clinical point: Majority of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) who switched from frontline second-generation (2G) tyrosine kinase inhibitor (TKI) to alternative TKIs because of intolerance or resistance were able to achieve or maintain favorable clinical outcomes.

Major finding: Among patients who switched because of intolerance, 88% achieved or maintained a major molecular response (MMR) with 5-year progression-free survival (PFS) and overall survival (OS) of 90.5% (95% confidence interval [CI], 90.4%-90.6%) and 95.2% (95% CI, 95.1%-95.3%), respectively. Among patients who switched because of resistance, 50% achieved or maintained an MMR with 5-year PFS and OS of 80.4% (95% CI, 80.2%-80.6%) and 80.0% (95% CI, 79.8%-80.2%).

Study details: Findings are from a retrospective analysis of 232 patients with newly diagnosed CML-CP treated with frontline 2G-TKI (dasatinib, n=187; nilotinib, n=45) who subsequently switched to alternative TKI.

Disclosures: This study was supported by Pharmacy Services, Alberta Health Services. K Jamani and L Savoie received honoraria from Novartis, Pfizer, Bristol Myers Squibb, and Paladin.

Source: Ma CE et al. Leuk Res. 2021 Jul 24. doi: 10.1016/j.leukres.2021.106674.

Key clinical point: Patients with chronic-phase chronic myeloid leukemia (CML-CP) who achieved an early (within 24 months) complete cytogenetic response (CCyR) to tyrosine kinase inhibitor (TKI) therapy (responders) had more favorable outcomes. However, continued TKI therapy led to late responses in a proportion of patients initially refractory to TKIs (nonresponders).

Major finding: During a median follow-up of 8.1 years, responders vs non-responders had significantly higher overall survival (93% vs 85%) and progression-free survival (93% vs 75%; both P less than .001) and lower progression to blast phase (1.9% vs 10.4%; P = .004). However, 34% of early nonresponders achieved CCyR with continued TKI therapy.

Study details: Findings are from a retrospective analysis of 305 adult patients with CML-CP treated with TKIs between 2001 and 2014.

Disclosures: This work was supported by the Thomas H. Brown Research Fund for Blood Cancers. M Talpaz reported ties with Novartis US and Takeda. Other authors declared no conflict of interests.

Source: Shaya J et al. Clin Lymphoma Myeloma Leuk. 2021 Jul 18. doi: 10.1016/j.clml.2021.07.001.

Key clinical point: Patients with chronic-phase chronic myeloid leukemia (CML-CP) who achieved an early (within 24 months) complete cytogenetic response (CCyR) to tyrosine kinase inhibitor (TKI) therapy (responders) had more favorable outcomes. However, continued TKI therapy led to late responses in a proportion of patients initially refractory to TKIs (nonresponders).

Major finding: During a median follow-up of 8.1 years, responders vs non-responders had significantly higher overall survival (93% vs 85%) and progression-free survival (93% vs 75%; both P less than .001) and lower progression to blast phase (1.9% vs 10.4%; P = .004). However, 34% of early nonresponders achieved CCyR with continued TKI therapy.

Study details: Findings are from a retrospective analysis of 305 adult patients with CML-CP treated with TKIs between 2001 and 2014.

Disclosures: This work was supported by the Thomas H. Brown Research Fund for Blood Cancers. M Talpaz reported ties with Novartis US and Takeda. Other authors declared no conflict of interests.

Source: Shaya J et al. Clin Lymphoma Myeloma Leuk. 2021 Jul 18. doi: 10.1016/j.clml.2021.07.001.

Key clinical point: Patients with chronic-phase chronic myeloid leukemia (CML-CP) who achieved an early (within 24 months) complete cytogenetic response (CCyR) to tyrosine kinase inhibitor (TKI) therapy (responders) had more favorable outcomes. However, continued TKI therapy led to late responses in a proportion of patients initially refractory to TKIs (nonresponders).

Major finding: During a median follow-up of 8.1 years, responders vs non-responders had significantly higher overall survival (93% vs 85%) and progression-free survival (93% vs 75%; both P less than .001) and lower progression to blast phase (1.9% vs 10.4%; P = .004). However, 34% of early nonresponders achieved CCyR with continued TKI therapy.

Study details: Findings are from a retrospective analysis of 305 adult patients with CML-CP treated with TKIs between 2001 and 2014.

Disclosures: This work was supported by the Thomas H. Brown Research Fund for Blood Cancers. M Talpaz reported ties with Novartis US and Takeda. Other authors declared no conflict of interests.

Source: Shaya J et al. Clin Lymphoma Myeloma Leuk. 2021 Jul 18. doi: 10.1016/j.clml.2021.07.001.

Key clinical point: Among patients with chronic myeloid leukemia (CML) presenting with COVID-19, better prognosis was observed in patients with controlled disease and those on tyrosine kinase inhibitor (TKI) therapies.

Major finding: Patients with vs without major molecular response had superior overall survival (91% vs 61%; P = .0004). Moreover, patients in treatment-free remission (100%) or on TKI therapy (89%) had higher survival vs patients who underwent hematopoietic stem cell transplantation (50%) or not receiving TKI treatment (33%; P < .001).

Study details: Findings are from an observational study assessing COVID-19 outcomes in 92 patients with CML in Latin America between March and December 2020.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Pagnano KB et al. Leuk Lymphoma. 2021 Jul 13. doi: 10.1080/10428194.2021.1950709.

Key clinical point: Among patients with chronic myeloid leukemia (CML) presenting with COVID-19, better prognosis was observed in patients with controlled disease and those on tyrosine kinase inhibitor (TKI) therapies.

Major finding: Patients with vs without major molecular response had superior overall survival (91% vs 61%; P = .0004). Moreover, patients in treatment-free remission (100%) or on TKI therapy (89%) had higher survival vs patients who underwent hematopoietic stem cell transplantation (50%) or not receiving TKI treatment (33%; P < .001).

Study details: Findings are from an observational study assessing COVID-19 outcomes in 92 patients with CML in Latin America between March and December 2020.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Pagnano KB et al. Leuk Lymphoma. 2021 Jul 13. doi: 10.1080/10428194.2021.1950709.

Key clinical point: Among patients with chronic myeloid leukemia (CML) presenting with COVID-19, better prognosis was observed in patients with controlled disease and those on tyrosine kinase inhibitor (TKI) therapies.

Major finding: Patients with vs without major molecular response had superior overall survival (91% vs 61%; P = .0004). Moreover, patients in treatment-free remission (100%) or on TKI therapy (89%) had higher survival vs patients who underwent hematopoietic stem cell transplantation (50%) or not receiving TKI treatment (33%; P < .001).

Study details: Findings are from an observational study assessing COVID-19 outcomes in 92 patients with CML in Latin America between March and December 2020.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Pagnano KB et al. Leuk Lymphoma. 2021 Jul 13. doi: 10.1080/10428194.2021.1950709.

Key clinical point: Long-term analysis indicated clear growth deceleration over time during nilotinib treatment in pediatric patients with newly diagnosed or imatinib/dasatinib resistant/intolerant Philadelphia chromosome-positive (Ph⁺) chronic myeloid leukemia (CML).

Major finding: Overall median change in height standard deviation scores after 48 cycles of nilotinib treatment vs baseline was −0.54 (range, −1.6 to 0.4) in patients resistant/intolerant to imatinib or dasatinib and −0.91 (range, −1.4 to −0.1) in patients with newly diagnosed CML. No new safety concerns were reported.

Study details: Findings are from the phase 2 DIALOG study including 58 pediatric patients with newly diagnosed (n=25) or imatinib or dasatinib resistant/intolerant (n=33) Ph⁺ CML who received at least 48 cycles of nilotinib treatment or discontinued the study.

Disclosures: This study was sponsored and funded by Novartis Pharmaceuticals Corporation. Some investigators including the lead author reported ties with Novartis.

Source: Hijiya N et al. Blood Adv. 2021 Jul 26. doi: 10.1182/bloodadvances.2020003759.

Key clinical point: Long-term analysis indicated clear growth deceleration over time during nilotinib treatment in pediatric patients with newly diagnosed or imatinib/dasatinib resistant/intolerant Philadelphia chromosome-positive (Ph⁺) chronic myeloid leukemia (CML).

Major finding: Overall median change in height standard deviation scores after 48 cycles of nilotinib treatment vs baseline was −0.54 (range, −1.6 to 0.4) in patients resistant/intolerant to imatinib or dasatinib and −0.91 (range, −1.4 to −0.1) in patients with newly diagnosed CML. No new safety concerns were reported.

Study details: Findings are from the phase 2 DIALOG study including 58 pediatric patients with newly diagnosed (n=25) or imatinib or dasatinib resistant/intolerant (n=33) Ph⁺ CML who received at least 48 cycles of nilotinib treatment or discontinued the study.

Disclosures: This study was sponsored and funded by Novartis Pharmaceuticals Corporation. Some investigators including the lead author reported ties with Novartis.

Source: Hijiya N et al. Blood Adv. 2021 Jul 26. doi: 10.1182/bloodadvances.2020003759.

Key clinical point: Long-term analysis indicated clear growth deceleration over time during nilotinib treatment in pediatric patients with newly diagnosed or imatinib/dasatinib resistant/intolerant Philadelphia chromosome-positive (Ph⁺) chronic myeloid leukemia (CML).

Major finding: Overall median change in height standard deviation scores after 48 cycles of nilotinib treatment vs baseline was −0.54 (range, −1.6 to 0.4) in patients resistant/intolerant to imatinib or dasatinib and −0.91 (range, −1.4 to −0.1) in patients with newly diagnosed CML. No new safety concerns were reported.

Study details: Findings are from the phase 2 DIALOG study including 58 pediatric patients with newly diagnosed (n=25) or imatinib or dasatinib resistant/intolerant (n=33) Ph⁺ CML who received at least 48 cycles of nilotinib treatment or discontinued the study.

Disclosures: This study was sponsored and funded by Novartis Pharmaceuticals Corporation. Some investigators including the lead author reported ties with Novartis.

Source: Hijiya N et al. Blood Adv. 2021 Jul 26. doi: 10.1182/bloodadvances.2020003759.

Key clinical point: Higher incidence of uncontrolled blood pressure (BP) was observed in patients with chronic myeloid leukemia (CML) receiving nilotinib vs imatinib or dasatinib, which may be involved in the pro-atherogenic mechanism underlying the development of cardiovascular disease in nilotinib-treated patients.

Major finding: Overall, 47.9% of patients were hypertensive and 32.9% of patients showed uncontrolled BP (at least 130/80 mmHg) on 24-hour ambulatory BP monitoring (ABPM). Patients receiving nilotinib vs dasatinib or imatinib showed a higher incidence of uncontrolled BP in ABPM (45.5% vs 20%; P = .041).

Study details: This observational study assessed clinical BP and 24-hour ambulatory BP in 73 patients with CML receiving active tyrosine kinase inhibitor treatment with either imatinib, nilotinib, or dasatinib.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Roa-Chamorro R et al. Sci Rep. 2021 Jul 19. doi: 10.1038/s41598-021-94127-2.

Key clinical point: Higher incidence of uncontrolled blood pressure (BP) was observed in patients with chronic myeloid leukemia (CML) receiving nilotinib vs imatinib or dasatinib, which may be involved in the pro-atherogenic mechanism underlying the development of cardiovascular disease in nilotinib-treated patients.

Major finding: Overall, 47.9% of patients were hypertensive and 32.9% of patients showed uncontrolled BP (at least 130/80 mmHg) on 24-hour ambulatory BP monitoring (ABPM). Patients receiving nilotinib vs dasatinib or imatinib showed a higher incidence of uncontrolled BP in ABPM (45.5% vs 20%; P = .041).

Study details: This observational study assessed clinical BP and 24-hour ambulatory BP in 73 patients with CML receiving active tyrosine kinase inhibitor treatment with either imatinib, nilotinib, or dasatinib.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Roa-Chamorro R et al. Sci Rep. 2021 Jul 19. doi: 10.1038/s41598-021-94127-2.

Key clinical point: Higher incidence of uncontrolled blood pressure (BP) was observed in patients with chronic myeloid leukemia (CML) receiving nilotinib vs imatinib or dasatinib, which may be involved in the pro-atherogenic mechanism underlying the development of cardiovascular disease in nilotinib-treated patients.

Major finding: Overall, 47.9% of patients were hypertensive and 32.9% of patients showed uncontrolled BP (at least 130/80 mmHg) on 24-hour ambulatory BP monitoring (ABPM). Patients receiving nilotinib vs dasatinib or imatinib showed a higher incidence of uncontrolled BP in ABPM (45.5% vs 20%; P = .041).

Study details: This observational study assessed clinical BP and 24-hour ambulatory BP in 73 patients with CML receiving active tyrosine kinase inhibitor treatment with either imatinib, nilotinib, or dasatinib.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Roa-Chamorro R et al. Sci Rep. 2021 Jul 19. doi: 10.1038/s41598-021-94127-2.

Key clinical point: Treatment with new-generation tyrosine kinase inhibitors (TKIs), i.e., bosutinib, nilotinib, and ponatinib, but not dasatinib, increased the risk of hepatotoxicity compared with imatinib among patients with chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Overall, patients receiving new-generation TKIs vs imatinib were at an increased risk of all-grade alanine aminotransferase (ALT) elevation (relative risk [RR], 2.89), high-grade ALT elevation (RR, 4.36), all-grade aspartate aminotransferase (AST) elevation (RR, 2.20), and high-grade AST elevation (RR, 2.65; all P < .001). Dasatinib was not associated with an increased risk of ALT or AST elevation.

Study details: Findings are from a systematic review and meta-analysis of 9 studies, including 3,475 patients with CML-CP that compared hepatotoxicity of bosutinib, dasatinib, nilotinib, and ponatinib vs imatinib.

Disclosures: This work was funded by the National Key Research and Development Program of China and the Fundamental Research Funds for the Central Universities. The authors did not report any conflict of interests.

Source: Wang Z et al. JAMA Netw Open. 2021 Jul 22. doi: 10.1001/jamanetworkopen.2021.20165.

Key clinical point: Treatment with new-generation tyrosine kinase inhibitors (TKIs), i.e., bosutinib, nilotinib, and ponatinib, but not dasatinib, increased the risk of hepatotoxicity compared with imatinib among patients with chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Overall, patients receiving new-generation TKIs vs imatinib were at an increased risk of all-grade alanine aminotransferase (ALT) elevation (relative risk [RR], 2.89), high-grade ALT elevation (RR, 4.36), all-grade aspartate aminotransferase (AST) elevation (RR, 2.20), and high-grade AST elevation (RR, 2.65; all P < .001). Dasatinib was not associated with an increased risk of ALT or AST elevation.

Study details: Findings are from a systematic review and meta-analysis of 9 studies, including 3,475 patients with CML-CP that compared hepatotoxicity of bosutinib, dasatinib, nilotinib, and ponatinib vs imatinib.

Disclosures: This work was funded by the National Key Research and Development Program of China and the Fundamental Research Funds for the Central Universities. The authors did not report any conflict of interests.

Source: Wang Z et al. JAMA Netw Open. 2021 Jul 22. doi: 10.1001/jamanetworkopen.2021.20165.

Key clinical point: Treatment with new-generation tyrosine kinase inhibitors (TKIs), i.e., bosutinib, nilotinib, and ponatinib, but not dasatinib, increased the risk of hepatotoxicity compared with imatinib among patients with chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Overall, patients receiving new-generation TKIs vs imatinib were at an increased risk of all-grade alanine aminotransferase (ALT) elevation (relative risk [RR], 2.89), high-grade ALT elevation (RR, 4.36), all-grade aspartate aminotransferase (AST) elevation (RR, 2.20), and high-grade AST elevation (RR, 2.65; all P < .001). Dasatinib was not associated with an increased risk of ALT or AST elevation.

Study details: Findings are from a systematic review and meta-analysis of 9 studies, including 3,475 patients with CML-CP that compared hepatotoxicity of bosutinib, dasatinib, nilotinib, and ponatinib vs imatinib.

Disclosures: This work was funded by the National Key Research and Development Program of China and the Fundamental Research Funds for the Central Universities. The authors did not report any conflict of interests.

Source: Wang Z et al. JAMA Netw Open. 2021 Jul 22. doi: 10.1001/jamanetworkopen.2021.20165.